Vertex announces UK approval for CASGEVY™
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read Details“Modality Solutions is pleased to be recognized for the second year in a row for our sustained managed growth in the Houston region,” said President Gary Hutchinson. “Our mission is to help our clients successfully launch new therapies and assist them in preparing for regulatory reviews. And I’m proud to say our team is made up of the brightest engineering professionals in biopharmaceutical cold chain logistics.”
Modality solutions reported a two-year (2017-2019) revenue growth of 65 percent. It moved up from No. 90 on the Fast 100 2019 list to No. 62 on the 2020 list.
“Amid the challenging business environment of COVID-19, the Houston Business Journal is proud to once again recognize the fastest-growing private companies in Houston,” said Bob Charlet, Publisher. The rankings were revealed during a live online broadcast September 18.
To view our formal Fast 100 press release, click here.
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read DetailsCongratulations to Melinta Therapeutics for their FDA Approval of REZZAYO™ for the Treatment of...
read DetailsCongratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read Details